ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Actinium Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$1.32+0.19 (+16.81%)
Close on Oct 19, 2026
- Market cap
- $41.46M
- P/E (TTM)
- 3.7
- Dividend yield
- –
Actinium Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Actinium Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $41.50M | $166.30M |
| Enterprise Value | $5.03M | $88.19M |
| PE Ratio | 3.67 | 20.44 |
| PB Ratio | 1.37 | 2.03 |
| P/TBV Ratio | 1.37 | 2.29 |
Enterprise value
| Measure | Actinium Pharmaceuticals | Industry median |
|---|---|---|
| EV / EBITDA | 0.51 | 14.65 |
| EV / EBIT | 0.53 | 19.00 |
Income (trailing twelve months)
| Measure | Actinium Pharmaceuticals | Industry median |
|---|---|---|
| Operating Income | $9.56M | -$21.40M |
| Net Income | $11.31M | -$22.46M |
| EBITDA | $9.78M | -$16.91M |
| EPS (Diluted) | $0.36 | -$0.83 |
Returns
| Measure | Actinium Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | 45.9% | -53.2% |
| Return on Assets (ROA) | 21.9% | -40.9% |
| Return on Capital Employed (ROCE) | 30.9% | -38.1% |
Growth
| Measure | Actinium Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -55.6% | 2.25% |
Balance sheet
| Measure | Actinium Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $36.47M | $61.43M |
| Net Cash (Debt) | $36.47M | $15.35M |
| Net Cash Per Share | $1.16 | $0.66 |
| Equity (Book Value) | $30.30M | $49.09M |
| Book Value Per Share | $0.96 | $1.37 |
| Tangible Book Value | $30.30M | $23.52M |
| Working Capital | $28.48M | $76.81M |
Financial position
| Measure | Actinium Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 4.08 | 3.34 |
| Quick Ratio | 3.94 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Actinium Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$22.66M | -$12.35M |
Efficiency
| Measure | Actinium Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | $452.32K | -$703.34K |
| Employee Count | 25 | 74 |
Dividends and yields
| Measure | Actinium Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 27.2% | -23.3% |
Shares
| Measure | Actinium Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 31,441,400 | 58,127,000 |
| Shares Change (YoY) | 0.30% | 10.9% |
| Shares Change (QoQ) | 0.21% | 0.54% |
| Float | 29,832,000 | 49,136,700 |
| Shares Held by Insiders | 5.12% | 11.6% |
| Shares Held by Institutions | 16.8% | 59.4% |
Scores
| Measure | Actinium Pharmaceuticals | Industry median |
|---|---|---|
| Graham Number | $2.79 | $18.73 |
| Graham Upside | 111.7% | -45.1% |
| Altman Z-Score | -9.34 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Actinium Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.